Latest / The Psychology Undergrad Podcast / Psychoactive Drugs Explained: How Drugs Are Classified and Scheduled
Transcript
- 0:00Welcome to this psychology undergrad. So if you
- 0:04take a double dose of aspirin to kill a stubborn
- 0:06migraine, society just calls you careless. Right,
- 0:10yeah. But if you take a prescription opioid just
- 0:12to relax after a brutal day at work, suddenly
- 0:14society calls you an abuser. Oh, exactly. It's
- 0:16a huge shift in perception. Right. And the chemical
- 0:19action hasn't fundamentally changed. I mean,
- 0:21a molecule is just a key turning a lock in your
- 0:23nervous system. The molecule itself doesn't have
- 0:26any morals. No, it really doesn't. Yet our entire
- 0:28vocabulary, our laws, our cultural perception
- 0:32of drugs, they're all just heavily loaded with
- 0:35judgment. So, we're taking on the roles of your
- 0:38study buddies today, tackling this massive interface
- 0:41between human behavior, society, and neurochemistry.
- 0:44Yeah, we're specifically doing a deep dive into
- 0:46chapter one of our psychopharmacology text today.
- 0:49And, well, what stands out to me immediately
- 0:51is how impossible it is to separate the hard
- 0:54biological science from all that sociological
- 0:56baggage you just mentioned. It's completely entangled.
- 0:59It really is. To even study how these psychoactive
- 1:03drugs alter human behavior, we have to navigate
- 1:07this crazy maze of shifting definitions, a century
- 1:11of morally driven legislation, and of course,
- 1:14the modern realities of a billion dollar pharmaceutical
- 1:16industry. It's a lot for one chapter. So let's
- 1:19start with the language itself, because that's
- 1:21where the foundation is for you guys listening.
- 1:24Yeah, definitions are key here. We're looking
- 1:25at chemicals that influence physiological function.
- 1:28Specifically the psychoactive ones, which are
- 1:31the ones that actually cross the blood -brain
- 1:33barrier to alter your behavior and your mood.
- 1:34Right. But the moment a chemical is synthesized
- 1:38in a lab, it gets wrapped in a very specific
- 1:40nomenclature. To keep this straight for the material,
- 1:44I've been using this little memory framework
- 1:45I call the three N's of naming. Okay, the three
- 1:48N's. I like that. Yeah, so you've got the nerd
- 1:50name, the normal name, and the neon name. That
- 1:52actually makes perfect sense. So the nerd name,
- 1:54that would be the chemical designation, right?
- 1:56The one dictated by the IU back standards. It's
- 1:59a literal structural map of the molecule, which
- 2:02is vital for a chemist who's trying to synthesize
- 2:04the compound, but it is completely impractical
- 2:07for a normal consumer, or even a prescribing
- 2:10doctor, really. Yeah, like let me read the nerd
- 2:12name for ibuprofen from the textbook. Wait, let
- 2:15me get this right. It's RS -2. dash four, dash
- 2:20two, methylpropylphenolpropanoic acid. Wow. Yeah,
- 2:24you're definitely not walking into a CVS and
- 2:26asking the pharmacist for a specific configuration
- 2:28of propanoic acid. Right, no way. You asked for
- 2:31the normal name. Yeah. And that's the generic
- 2:33classification approved by the US adopted name
- 2:36council. So in that case, just ibuprofen. Or
- 2:38acetaminophen, yeah. But then, and this is where
- 2:41the money comes in, the manufacturer slaps a
- 2:43trademark on it, they put it in bright shiny
- 2:46packaging, and we get the neon name. The brand
- 2:48name, like Advil or Motrin or Tylenol. Exactly.
- 2:51It's the exact same generic chemical, but that
- 2:54neon branding entirely changes how the public
- 2:56interacts with it. And that distinction between
- 2:58what a drug actually is and how it's perceived,
- 3:01that bleeds directly into how we classify its
- 3:03use in clinical settings. It really does. Yeah.
- 3:05Like the text draws this hard line between therapeutic
- 3:09use, which is, you know, treating a specific
- 3:11ailment, and recreational use, which is just
- 3:14seeking the pharmacological effects for pleasure.
- 3:17And that line right there is exactly where the
- 3:19scientific terminology starts getting super entangled
- 3:21with cultural morality. Oh, 100%. Historically,
- 3:24clinical language categorized behaviors as use,
- 3:27misuse, and abuse. Use just being the prescribed
- 3:30normal baseline. Misuse covered improper handling.
- 3:35So taking your spouse's medication because your
- 3:37back hurts, or skipping doses, or stopping your
- 3:39antibiotics early. Which people do all the time.
- 3:41Constantly. But abuse was strictly defined as
- 3:45use with the primary intent of experiencing pleasure
- 3:48or intentionally altering your state of consciousness.
- 3:51And here is where I get really - really hung
- 3:53up on the terminology. And I think it's important
- 3:55for you guys reviewing this to catch this nuance.
- 3:58The National Institute on Drug Abuse and the
- 4:00DSM -5, they are actively trying to phase out
- 4:03the word abuse entirely. They want everyone to
- 4:07use substance use disorder or just misuse. Yeah,
- 4:09that's a massive shift in the literature. It
- 4:12is. And I think some people hear that and assume
- 4:14it's just modern clinical spaces trying to sanitize
- 4:17language or just be politically correct. But
- 4:20if you actually look at the mechanisms of addiction,
- 4:22The word abuse is just fundamentally inaccurate
- 4:26to what is happening neurologically. Exactly,
- 4:29because the term abuse carries this implicit
- 4:31judgment. It's a moral failing. It suggests the
- 4:35user is making this conscious, malicious choice
- 4:37to quote unquote abuse a substance. Right, like
- 4:42they're just behaving badly. Yeah. But the clinical
- 4:44shift to substance use disorder actually reflects
- 4:48our modern understanding of the brain's reward
- 4:50pathways. I mean, we really have to separate
- 4:52physiological dependence from addiction here.
- 4:54Yeah, let's break that down because they are
- 4:56not the same thing. Right. Dependence is purely
- 4:58a mechanical adaptation. Your body just builds
- 5:01tolerance. It down -regulates its own natural
- 5:04neurotransmitter production in response to this
- 5:06external chemical flood. Which just means you
- 5:09literally need higher doses to achieve normal
- 5:12homeostasis. And if you stop taking it, you experience
- 5:15physical withdrawal. Exactly. And anyone can
- 5:18become dependent. A patient taking prescribed
- 5:21pain medication strictly as directed for, like,
- 5:24a shattered femur. they will become physically
- 5:27dependent. Yeah, their body will go through withdrawal
- 5:29if they just stop cold turkey. Yeah. but they
- 5:31aren't necessarily addicted. Right. Addiction
- 5:33introduces the behavioral compulsion. It's that
- 5:36self -reinforcing loop where the user continues
- 5:38seeking the drug despite catastrophic harm to
- 5:41their life, their relationships, their health.
- 5:43And the textbook points out that this physiological
- 5:45loop of addiction actually overrides the prefrontal
- 5:49cortex, which is the decision -making center
- 5:51of the brain. It completely hijacks it. When
- 5:54a psychoactive substance floods the brain with
- 5:56dopamine, it's often at levels that are just
- 5:58exponentially higher than natural reward. like
- 6:00higher than food or social interaction. So the
- 6:03brain's learning mechanisms are just overwhelmed.
- 6:06Yeah. The brain basically flags that chemical
- 6:09as essential for survival. It prioritizes it
- 6:12above literally everything else. So calling that
- 6:14biological hijacking bad behavior just a moral
- 6:16failing, it completely ignores the actual physical
- 6:19rewiring of the neurology. Right. But if it is
- 6:22a physiological rewiring, it begs the question
- 6:25of vulnerability. Like, why does one person take
- 6:28a prescribed opioid and just walk away the moment
- 6:31their prescription ends, while someone else takes
- 6:33the exact same dose and spirals into a decade
- 6:36-long substance use disorder? That is the big
- 6:39question. The textbook maps this out through
- 6:41something we can visualize as the triangle of
- 6:43the drug experience. So for your notes, picture
- 6:46three vertices. The substance, the self, and
- 6:49the setting. I love that framework. OK, so the
- 6:51substance encompasses the purely pharmacological
- 6:54factors, the drug itself, the dosage, the chemical
- 6:57half -life, and crucially, the route of administration.
- 7:01Right, how it gets into your body. Exactly. The
- 7:03delivery method dictates the pharmacokinetics.
- 7:06So injecting or inhaling a substance forces it
- 7:09across the blood -brain barrier almost instantly.
- 7:12That creates a massive, super -rapid spike in
- 7:15dopamine. Way faster than if you swallowed a
- 7:16pill. Way faster. And that rapid onset is just
- 7:20far more reinforcing to the brain's reward circuitry
- 7:23than, say, a slow -release oral capsule. The
- 7:26brain learns that association between the action
- 7:28and the intense reward much, much faster. But
- 7:32the substance is only one point of the triangle.
- 7:34The other two, the self and the setting, are
- 7:37entirely non -pharmacological. The self covers
- 7:40your genetics, your baseline neurochemistry,
- 7:43and your individual psychological state at the
- 7:45exact moment of ingestion. And then the setting
- 7:49is the external environment. So your peer groups,
- 7:52your socioeconomic stability, literally the physical
- 7:55room you're in. when you use it. Yeah, the context.
- 7:57And I need to unpack the mechanics of this because
- 7:59it challenges a lot of assumptions for me. Like,
- 8:02are we really saying that if two people take
- 8:04the exact same chemical, the exact same dose,
- 8:06same route of administration, their brains will
- 8:10literally process that pharmacological reward
- 8:12differently based purely on their environment?
- 8:14Yes. Absolutely, yes. Because the brain doesn't
- 8:17process chemical inputs in a vacuum. Let's look
- 8:19at the mechanism of reinforcement here. You have
- 8:21positive reinforcement, which is taking a drug
- 8:24to feel a novel sense of euphoria, just to feel
- 8:27good. And then you have negative reinforcement,
- 8:30which is taking a drug to remove profound psychological
- 8:34or physical pain. So running away from a bad
- 8:36feeling versus chasing a good one. Exactly. And
- 8:39the brain's survival architecture weights negative
- 8:42reinforcement really heavily. If someone is utilizing
- 8:45a substance to escape, say, a traumatic home
- 8:48life, the psychological relief amplifies the
- 8:51reinforcement of that reward pathway. Wow. The
- 8:53drug isn't just providing pleasure anymore. It
- 8:55is literally turning off of a fire alarm in their
- 8:58nervous system. So the neuroplasticity is actually
- 9:00primed by the environment. Yes. The person taking
- 9:03the drug in a safe, well -adjusted setting, they
- 9:06still experience the dopamine spike, but their
- 9:08brain hasn't been like. Starved of stability.
- 9:10Yeah, so the reinforcement doesn't lock in with
- 9:13the same ferronity the environment actually dictates
- 9:15your vulnerability to the chemical which as you
- 9:18can imagine presents an enormous problem for
- 9:20lawmakers a government cannot regulate a user's
- 9:23psychological state they can't legislate your
- 9:25living room environment the law can only target
- 9:28the physical substance itself and attempting
- 9:31to objectively regulate highly subjective context
- 9:35dependent experiences Well, it has resulted in
- 9:39a century of legislative whiplash in this country.
- 9:42Yeah, we have to look at how these substances
- 9:44are legally categorized before we get into that
- 9:46history, because the legal vocabulary is just
- 9:49as rigid as the chemical nomenclature we talked
- 9:51about earlier. Oh, definitely. The text divides
- 9:53them into legend versus non -legend drugs. Legend
- 9:58drugs are the FDA -approved medications that
- 10:00require a prescription. They literally used to
- 10:03carry a printed legend on the bottle, stating
- 10:06that federal law prohibits dispensing with that
- 10:08one. Right, and non -legend are just your over
- 10:10-the -counter meds. Exactly. And then there's
- 10:12the divide between controlled and non -controlled.
- 10:15So controlled substances are those deemed to
- 10:18have an abuse potential, and those fall directly
- 10:20under the jurisdiction of the DEA, Drug Enforcement
- 10:23Administration. Non -controlled legend drugs,
- 10:25like say a standard blood pressure medication,
- 10:28they still require a prescription, but they aren't
- 10:30heavily monitored by the DEA for diversion or
- 10:33street sale because nobody's getting high off
- 10:36them. Makes sense. And finally, we have the illicit
- 10:38versus illicit categorization. Illicit substances
- 10:42are legally manufactured and distributed for
- 10:44medical or recreational use, like alcohol or
- 10:47prescribed amphetamines. Illicit substances have
- 10:49no federally recognized medical application and
- 10:52are strictly prohibited, like heroin or LSD.
- 10:55Right, and the DEA categorizes those controlled
- 10:57substances into five specific schedules. Okay,
- 11:01yeah, my memory aid for you guys on this one.
- 11:02I visualized the DEA schedules like an upside
- 11:05-down VIP club. An upside -down VIP club. Yeah,
- 11:08so schedule A is the absolute most exclusive
- 11:11restrictive tier. You cannot get a prescription
- 11:14to get in no matter what. The federal government
- 11:16deems Schedule I drugs to have the highest potential
- 11:18for abuse and zero accepted medical use. Schedule
- 11:22II drugs also have a severe abuse potential,
- 11:25but they do have an accepted medical use, so
- 11:27you can get in with a highly restricted prescription.
- 11:29And then schedules third, four, and V represent
- 11:33progressively lower risks of dependence, and
- 11:36they have looser restrictions. Basically, schedule
- 11:39V is the general admission line. That's a great
- 11:41way to picture it. But the issue the textbook
- 11:44highlights is that the placement of substances
- 11:46within those five schedules rarely aligns with
- 11:49objective pharmacological risk. Well, it really
- 11:51doesn't. The history of US drug law is primarily
- 11:53a history of social panic and cultural engineering.
- 11:56It's not based on scientific consensus. which
- 11:59is wild to think about. I mean, for most of human
- 12:02history, psychoactive substances were completely
- 12:05unregulated. Indigenous cultures integrated hallucinogens
- 12:08like peyote into religious and social frameworks
- 12:11with complex rituals that actually mitigated
- 12:14abuse. And in 19th century America, opiates and
- 12:18cocaine were ubiquitous. They were in tonics.
- 12:20They were widely available to everyone. Right,
- 12:22but the legislative clampdown didn't start with
- 12:24clinical trials showing they were dangerous.
- 12:26It started with targeting specific demographics.
- 12:28Exactly. Like the 1875 San Francisco ban on public
- 12:32opium dens. That wasn't a public health initiative
- 12:34against opium because wealthy citizens were freely
- 12:37drinking it in the form of laudanum at home.
- 12:40Right. Nobody was resting them. Exactly. The
- 12:42ban was specifically targeted at Chinese immigrants.
- 12:45And even the 1906 Pure Food and Drug Act that
- 12:48merely required accurate labeling. It didn't
- 12:50actually restrict access to the drugs. The real
- 12:53structural shift, according to the text, happened
- 12:55with the Harrison Narcotics Tax Act of 1914.
- 12:59And the mechanics of the Harrison Act are crucial
- 13:01for you to understand for this chapter, because
- 13:03it didn't explicitly outlaw opiates or cocaine.
- 13:07It was framed purely as a revenue measure. It
- 13:10just required anyone importing, manufacturing,
- 13:12or dispensing these drugs to register and pay
- 13:15a tax. Right. But the enforcement mechanism is
- 13:17where the entire landscape changed. The law stated
- 13:20that physicians could prescribe these narcotics,
- 13:23quote, in the course of professional practice
- 13:25only. And the courts quickly decided that maintaining
- 13:28a patient's addiction was not a legitimate professional
- 13:31practice. Exactly. So overnight, Physicians who
- 13:34were just treating dependent patients were suddenly
- 13:37facing federal criminal charges. Wow. It shifted
- 13:40addiction entirely out of the medical sphere
- 13:42and shoved it directly into the criminal justice
- 13:45system. It forced the supply underground and
- 13:48it basically created the blueprint for the illicit
- 13:51drug trade. And we saw this exact same sociological
- 13:53mechanism play out on a massive scale just a
- 13:56few years later with the 18th Amendment in 1920
- 14:00prohibition. Right. Alcohol. This wasn't driven
- 14:03by neuroscientists analyzing the hepatotoxicity
- 14:06of alcohol. It was driven by the temperance movement,
- 14:09which was basically a coalition of moral and
- 14:11religious groups. And it was a spectacular failure.
- 14:13It didn't stop people from drinking. It just
- 14:15handed a massive, incredibly lucrative industry
- 14:18directly to organized crime. Which is exactly
- 14:20why it was repealed by 1933. But the government
- 14:24clearly didn't abandon the tactic of prohibition,
- 14:27because by 1937 they pushed through the Marijuana
- 14:29Tax Act, functionally criminalizing cannabis
- 14:32nation -wide. The culmination of this whole legislative
- 14:36philosophy was the 1970 Controlled Substances
- 14:40Act under the Nixon administration. That's what
- 14:43formally established the DEA schedules we just
- 14:46talked about and officially launched the war
- 14:48on drugs. It established total prohibition and
- 14:51criminalization as the absolute bedrock of American
- 14:54drug policy. And the punitive nature of this
- 14:57system got locked in with the 1984 Sentencing
- 15:00Reform Act. That's the one that introduced mandatory
- 15:02minimums, right? Yes. Mandatory minimum sentences
- 15:05based solely on the weight of the drug involved.
- 15:08It literally stripped judges of the ability to
- 15:11consider the context of the offense. So it completely
- 15:13ignored the self and the setting of the drug
- 15:15experience, punishing only the existence of the
- 15:18substance. Exactly. And we are currently watching
- 15:20the friction of this history play out in real
- 15:21time. Just look at the legal status of marijuana
- 15:24today. Under the DEA's Controlled Substances
- 15:26Act, it remains a schedule I drug. So the federal
- 15:30government's official stance is that it carries
- 15:32the absolute highest potential for abuse and
- 15:34has no medical utility whatsoever. Meanwhile,
- 15:38states all across the country have fully legalized
- 15:40it. They're regulating it for both medical and
- 15:42recreational markets. And, you know, we aren't
- 15:45evaluating the politics of legalization here.
- 15:48We're not taking a stance on the left or the
- 15:49right. No, no, just looking at the facts. Right.
- 15:52But from a purely academic standpoint, you have
- 15:55federal and state governments operating in completely
- 15:58contradictory realities regarding the exact same
- 16:01molecular structure. It's fascinating. It proves
- 16:03that our legal classifications are basically
- 16:06living documents. They are reactive to public
- 16:09sentiment, to lobbying, and to shifting cultural
- 16:12norms, not just peer -reviewed pharmacology.
- 16:15But when we look at the drugs that do fall into
- 16:18the licit category, the federally approved, legally
- 16:21prescribed medications, we run into an entirely
- 16:24different set of systemic issues. Because bringing
- 16:26a new psychopharmacological treatment to market
- 16:29requires navigating a process so fraught with
- 16:32failure, it actually shapes the entire economic
- 16:35structure of modern health care. The textbook
- 16:37calls it this 10 plus year journey, and it really
- 16:40acts as a massive funnel of failure. A pharmaceutical
- 16:43company might synthesize and analyze anywhere
- 16:46from five thousand 10 ,000 novel chemical compounds
- 16:50in a laboratory just to start. And out of those
- 16:53thousands, maybe 250 show enough promise to even
- 16:56advance to preclinical trials. Right. And preclinical
- 16:59involves in vitro testing on cell cultures and
- 17:02in vivo testing on animal models just to check
- 17:05for basic toxicity and pharmacokinetics. But
- 17:07the attrition rate there is enormous because
- 17:10animal models often just fail to translate to
- 17:13human biology. They really do. So out of those
- 17:15250 preclinical candidates, an average of only
- 17:18five will actually generate the safety data required
- 17:21to submit an investigational new drug application
- 17:24to the FDA. Just five. Just five. Yeah. And if
- 17:26that IND is approved, the drug finally enters
- 17:29the clinical trial phases. OK. And I map these
- 17:31out for my notes using the four S's. So phase
- 17:33one, is it safe? Safe. Yeah. This is a very small
- 17:37group of healthy volunteers. The goal isn't even
- 17:39to see if the drug cures the disease, it's strictly
- 17:42to establish the maximum tolerated dose and monitor
- 17:44for acute severe side effects. Then you have
- 17:46phase two, does it start to work? Start to work,
- 17:49right. They bring in a slightly larger group
- 17:51of patients who actually have the target condition
- 17:53and they utilize double blind placebo controls
- 17:57to measure efficacy against a baseline. And then
- 18:00phase three. Scale it up and phase three is where
- 18:03the financial burden just skyrockets You have
- 18:05to scale up to thousands of patients across diverse
- 18:08demographics and multiple clinical sites and
- 18:11the statistical logic here is non -negotiable
- 18:13Why is that? Well think about it if a drug causes
- 18:16a fatal liver complication in say one out of
- 18:19every 2 ,000 people a phase one or phase two
- 18:22trial of 50 people is completely Statistically
- 18:24blind to that danger you need massive sample
- 18:27sizes to uncover rare but catastrophic adverse
- 18:30effects Well, that makes sense. So if the data
- 18:32from phase three proves the drug is both safe
- 18:34and more effective than current treatments, the
- 18:36company submits a new drug application. And if
- 18:39the FDA approves it, which only happens for roughly
- 18:41one out of those five drugs that even entered
- 18:43clinical trials, it finally hits the pharmacy,
- 18:46and then it enters phase four. Surveillance,
- 18:49where the manufacturer continuously monitors
- 18:51the broader population for long -term effects
- 18:54that couldn't be caught during a finite trial.
- 18:56So from 10 ,000 initial compounds, you end up
- 18:59with one approved medication. And the financial
- 19:02reality of this funnel is just spaggering. The
- 19:05average cost to bring a single new drug to market
- 19:08is estimated at $985 million. That is insane.
- 19:12And complex biologics push closer to $2 .8 billion.
- 19:16To incentivize companies to take on that massive
- 19:19financial risk, the U .S. Patent and Trademark
- 19:22Office grants a 20 -year patent. During that
- 19:25window, the company holds an absolute monopoly.
- 19:28No one else can manufacture the generic version.
- 19:31But wait, the clock on that 20 -year patent starts
- 19:33ticking the moment they file it, right? Yes.
- 19:35And that usually happens during the early preclinical
- 19:37phase just to protect their intellectual property.
- 19:39So by the time the drug actually survives the
- 19:41decade -long gauntlet of clinical trials and
- 19:43FDA review, the company might only have 10 or
- 19:4512 years of market exclusivity left. And in that
- 19:48narrow window, they don't just have to recoup
- 19:51the billion dollars they spend developing that
- 19:53specific drug. They have to recoup the costs
- 19:56of the 9 ,999 compounds that failed. It operates
- 20:00exactly like venture capital. The single successful
- 20:03asset has to absorb the losses of the entire
- 20:06portfolio. And the structural necessity is exactly
- 20:09what leads to astronomical pricing. I mean, the
- 20:12text points out a recent FDA approved Alzheimer's
- 20:15medication that launched with an annual price
- 20:18tag of $56 ,000 per patient. Just for one year.
- 20:22Yes. While that patent expires and generic competitors
- 20:25can finally enter the market to drive the price
- 20:27down, the barrier to access remains purely financial.
- 20:31OK. The patent logic makes sense in theory if
- 20:34you assume all that revenue is being funneled
- 20:35directly back into laboratory research to find
- 20:37the next cure. But the data heavily contradicts
- 20:40that assumption. Oh, heavily. Like the text references
- 20:42a prominent report. I think John Oliver covered
- 20:44this on last week tonight, too, highlighting
- 20:46that nine out of the 10 largest pharmaceutical
- 20:49companies routinely spend more capital on marketing
- 20:52than they do on actual research and development.
- 20:54Yeah, the marketing ecosystem is vast. It's direct
- 20:57to consumer television advertising, which, by
- 21:00the way, is illegal in most developed nations
- 21:02outside the US and New Zealand. I didn't know
- 21:04that. Yeah. It's deploying armies of sales representatives
- 21:07to doctor's offices. It's funding continuing
- 21:10medical education seminars, providing massive
- 21:13volumes of free samples, and historically compensating
- 21:16physicians with consulting fees or even luxury
- 21:19travel just to incentivize prescription. If a
- 21:22company is spending more on maintaining a sales
- 21:26force or sending dockers on cruises than they
- 21:28are on synthesizing new compounds, it forces
- 21:31a really hard look at the ethics of the industry.
- 21:34The text introduces this concept of disease -mongering,
- 21:37which is the active medicalization of normal
- 21:39human experiences. If a company holds the patent
- 21:42on a drug that treats social anxiety, they are
- 21:44financially incentivized to expand the diagnostic
- 21:47boundaries of social anxiety through advertising.
- 21:50They're basically trying to convince a wider
- 21:52swath of the population that their everyday shyness
- 21:55is actually a pathology requiring a chemical
- 21:57intervention. It creates this toxic feedback
- 21:59loop where the line between legitimate medical
- 22:02education and the manufacturing of consumer demand
- 22:05completely dissolves. When healthcare operates
- 22:08as a heavily capitalized, profit -driven industry,
- 22:11the molecular science often takes a backseat
- 22:14to the demands of shareholders. Which brings
- 22:16our study session on Chapter 1 full circle. I
- 22:18mean, we started by looking at the sterile chemical
- 22:20structure of psychoactive drugs, the IUPIC nerd
- 22:23names, only to find out that the entire field
- 22:26is defined by human bias. It really is. We examined
- 22:30how the clinical language is trying to shed the
- 22:32moral judgments of terms like abuse, recognizing
- 22:35that addiction is a physiological rewiring that's
- 22:38deeply vulnerable to our psychological state
- 22:40and our physical environment. And we trace the
- 22:42history of how the legal system has attempted
- 22:45to regulate these chemical interactions, mostly
- 22:47relying on taxation, prohibition, and mandatory
- 22:50minimums, rather than actual pharmacological
- 22:53risk. Right. And finally, we mapped out the brutal
- 22:56billions architecture of modern drug development,
- 22:59where statistical necessity and patent law collide
- 23:02with aggressive marketing strategies. So the
- 23:05major takeaway from this chapter for you guys
- 23:07listening is that psychopharmacology is never
- 23:10just about what a molecule does to a receptor.
- 23:12No, not at all. It is the ultimate lens for understanding
- 23:15how our biology constantly collides with sociology,
- 23:19law, and economics. It's not just memorizing
- 23:21a textbook. Exactly. And I want to leave you
- 23:23with a final thought to process before you review
- 23:25these notes again. If our clinical understanding
- 23:28of addiction has shifted from a moral failure
- 23:30to a physiological mechanism, and if our legal
- 23:34classifications have constantly been rewritten
- 23:36by cultural panic rather than science, What will
- 23:39that DEA schedule look like in the year 2050?
- 23:43That's a great question. Will the illicit criminalized
- 23:45street drugs driving today's incarceration rates
- 23:48become the patented billion dollar heavily marketed
- 23:50mental health treatments of tomorrow? Something
- 23:53to think about. Keep questioning the material
- 23:55and we'll catch you on the next deep dive for
- 23:57the Psychology undergrad.